cancer type         dataset         p value         HR [95% CI]           Breast cancer         GSE12276         0.035         0.85 [0.73 - 0.99]         Image: Control of the con					
GSE6532 0.11 0.82 [0.64 - 1.05]  GSE9195 0.442 1.21 [0.75 - 1.95]  GSE1456 0.007 0.63 [0.45 - 0.88]  E-TABM-158 0.696 1.05 [0.82 - 1.35]  GSE7390 0.109 1.14 [0.97 - 1.35]  Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]	cancer type	dataset	p value	HR [95% CI]	
GSE9195 0.442 1.21 [0.75 - 1.95]  GSE1456 0.007 0.63 [0.45 - 0.88]  E-TABM-158 0.696 1.05 [0.82 - 1.35]  GSE7390 0.109 1.14 [0.97 - 1.35]  Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]	Breast cancer	GSE12276	0.035	0.85 [0.73 - 0.99]	<b>→</b>
GSE1456 0.007 0.63 [0.45 - 0.88]  E-TABM-158 0.696 1.05 [0.82 - 1.35]  GSE7390 0.109 1.14 [0.97 - 1.35]  Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]		GSE6532	0.11	0.82 [0.64 - 1.05]	<b></b>
E-TABM-158 0.696 1.05 [0.82 - 1.35]  GSE7390 0.109 1.14 [0.97 - 1.35]  Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]		GSE9195	0.442	1.21 [0.75 - 1.95]	<del>-  </del>
GSE7390 0.109 1.14 [0.97 - 1.35]  Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]		GSE1456	0.007	0.63 [0.45 - 0.88]	<b>⊢</b>
Head and neck cancer GSE2837 0.432 0.88 [0.65 - 1.20]  Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10]  GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]		E-TABM-158	0.696	1.05 [0.82 - 1.35]	<del></del>
Lung cancer GSE31210 0.196 0.83 [0.62 - 1.10] GSE8894 0.044 0.87 [0.76 - 1.00] GSE17710 0.539 0.93 [0.74 - 1.17] 0.5 1.0 1.5		GSE7390	0.109	1.14 [0.97 - 1.35]	<del> </del>
GSE8894 0.044 0.87 [0.76 - 1.00]  GSE17710 0.539 0.93 [0.74 - 1.17]  0.5 1.0 1.5	Head and neck cancer	GSE2837	0.432	0.88 [0.65 - 1.20]	<u> </u>
GSE17710 0.539 0.93 [0.74 - 1.17]	Lung cancer	GSE31210	0.196	0.83 [0.62 - 1.10]	<b>⊢</b> • <u> </u> †
0.5 1.0 1.5		GSE8894	0.044	0.87 [0.76 - 1.00]	+•
		GSE17710	0.539	0.93 [0.74 - 1.17]	<b>⊢</b> • <u></u> ⊢

Figure S1 Relationship between CLU expression and prognosis (relapse-free survival) in patients with different tumors in PrognoScan database. HR, hazard ratio; CI, confidence interval; CLU, clusterin.

	HR [95% CI]	p value	dataset	cancer type
H	0.79 [0.45 - 1.39]	0.415	GSE7378	Breast cancer
<b>н</b>	0.58 [0.41 - 0.83]	0.003	GSE4922	
<u> </u>	0.81 [0.21 - 3.04]	0.752	GSE12945	Colorectal cancer
<del>-</del>	1.11 [0.65 – 1.88]	0.698	GSE17536	
H <del>-</del>	1.12 [0.86 - 1.47]	0.408	GSE14333	
+	1.25 [0.84 - 1.85]	0.273	GSE17537	
юн	1.03 [0.93 - 1.14]	0.609	GSE26712	Ovarian cancer
1 2 CLU group control group				

Figure S2 Relationship between CLU expression and prognosis (disease-specific survival) in patients with different tumors in PrognoScan database. HR, hazard ratio; CI, confidence interval; CLU, clusterin.

cancer type	dataset	p value	HR [95% CI]	
Breast cancer	GSE19615	0.865	0.95 [0.51 - 1.76]	<b>⊢</b> •¹
	GSE6532	0.012	0.66 [0.48 - 0.91]	<b></b>
	GSE11121	0.007	0.63 [0.44 - 0.88]	<b></b> ;
	GSE2034	0.017	0.77 [0.61 - 0.95]	<b></b> ¦
	E-TABM-158	0.363	0.88 [0.67 - 1.16]	<b></b>
	GSE2990	0.713	1.06 [0.79 - 1.40]	<del>- ;</del>
	GSE7390	0.088	1.19 [0.97 - 1.46]	<del> </del>
Eye cancer	GSE22138	0.689	0.96 [0.77 - 1.19]	<b>—</b>
				0.4 0.8 1.2 1.6
				CLU group control group

**Figure S3** Relationship between CLU expression and prognosis (distant metastasis free survival) in patients with different tumors in PrognoScan database. HR, hazard ratio; CI, confidence interval; CLU, clusterin.

cancer type	dataset	p value	HR [95% CI]	
Blood cancer	GSE12417	0.001	1.26 [1.10 – 1.44]	H=-1
	GSE4475	0.584	0.95 [0.81 – 1.13]	H
Brain cancer	GSE4271	0.494	1.12 [0.82 – 1.53]	<u> </u>
Breast cancer	GSE9893	0.001	1.38 [1.15 – 1.65]	ļ <b>—</b>
	GSE1456	0.01	0.64 [0.45 – 0.90]	<b>→</b>
	GSE7390	0.205	1.14 [0.93 – 1.40]	<u> </u>
Colorectal cancer	GSE17536	0.179	1.23 [0.91 – 1.67]	1
	GSE17537	0.005	1.62 [1.16 – 2.27]	¦
Lung cancer	GSE31210	0.498	0.88 [0.61 – 1.27]	<b>⊢</b> • <u></u>
	GSE3141	0.023	0.74 [0.58 – 0.96]	<b>⊢•</b> ⊸i
	GSE4573	0.322	0.89 [0.70 – 1.12]	<del>⊢•</del> ∔
Ovarian cancer	GSE9891	0.913	1.01 [0.88 – 1.15]	+++
	DUKE-OC	0.261	1.08 [0.94 – 1.24]	H
Prostate cancer	GSE16560	0.001	0.58 [0.42 – 0.81]	<b>⊷</b>
Skin cancer	GSE19234	0.158	0.81 [0.61 – 1.08]	<b>⊢</b> •-∔
				0.5 1.0 1.5 2.0 CLU group control group

**Figure S4** Relationship between CLU expression and prognosis (overall survival) in patients with different tumors in PrognoScan database. HR, hazard ratio; CI, confidence interval; CLU, clusterin.